Amedisys, Inc. (NASDAQ:AMED) Stake Boosted by Alpine Associates Management Inc.

Alpine Associates Management Inc. grew its holdings in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 3.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 888,120 shares of the health services provider's stock after purchasing an additional 27,403 shares during the quarter. Amedisys comprises about 4.9% of Alpine Associates Management Inc.'s portfolio, making the stock its 7th biggest position. Alpine Associates Management Inc. owned approximately 2.71% of Amedisys worth $80,632,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Blue Trust Inc. increased its stake in Amedisys by 55.1% in the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock valued at $34,000 after purchasing an additional 124 shares in the last quarter. HBW Advisory Services LLC bought a new stake in Amedisys in the 4th quarter valued at about $38,000. Versant Capital Management Inc raised its stake in Amedisys by 68.5% during the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider's stock worth $41,000 after buying an additional 183 shares during the period. KBC Group NV acquired a new position in Amedisys during the 3rd quarter worth approximately $63,000. Finally, Venturi Wealth Management LLC boosted its holdings in Amedisys by 397.4% in the fourth quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider's stock worth $89,000 after acquiring an additional 779 shares in the last quarter. Institutional investors own 94.36% of the company's stock.

Remove Ads

Amedisys Stock Up 0.5 %

AMED traded up $0.47 during midday trading on Thursday, reaching $92.59. 216,494 shares of the company were exchanged, compared to its average volume of 379,063. The company has a market cap of $3.04 billion, a price-to-earnings ratio of 36.74, a price-to-earnings-growth ratio of 1.78 and a beta of 0.76. Amedisys, Inc. has a one year low of $82.15 and a one year high of $98.95. The company's fifty day moving average price is $92.08 and its 200 day moving average price is $92.85. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19.

Amedisys (NASDAQ:AMED - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing analysts' consensus estimates of $1.05 by ($0.09). The company had revenue of $598.05 million during the quarter, compared to analysts' expectations of $602.38 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. As a group, analysts expect that Amedisys, Inc. will post 4.4 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Stephens reaffirmed an "equal weight" rating and set a $101.00 target price on shares of Amedisys in a research report on Tuesday, March 4th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $100.75.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.